['non-small cell lung cancer']
['nivolumab']

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  ECOG Status: PS 0-1 & PS 2

          -  Subjects with histologically or cytologically-documented SqNSCLC

          -  Subjects must have experienced disease progression or recurrence during or after one
             prior platinum doublet-based chemotherapy regimen

          -  Subjects must have evaluable disease by CT or MRI per RECIST 1.1 criteria

          -  Subjects with treated or asymptomatic CNS metastases

          -  Prior palliative radiotherapy must have been completed at least 14 days prior to study
             drug administration

          -  Prior lines of antineoplastic therapy, including hemotherapy, hormonal therapy,
             immunotherapy, surgical resection of lesions, non-palliative radiation therapy, or
             standard or investigational agents for treatment of NSCLC, must be completed 28 days
             prior to the first dose of nivolumab

          -  Males and Females, ages 18 or older

        Exclusion Criteria:

          -  Subjects with untreated, symptomatic CNS metastases

          -  Subjects with carcinomatous meningitis

          -  Subjects with active, known or suspected autoimmune disease.

          -  Subjects who received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2,
             anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or
             drug specifically targeting T-cell costimulation or checkpoint pathways) or who have
             previously taken part in a randomized BMS clinical trial for nivolumab or ipilimumab.
      